{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:51:47Z","timestamp":1786121507907,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euf.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:21:50Z","timestamp":1777944110000},"page":"622-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Singh and Srivastav\u2019s Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. 2026;12:393\u2013402"],"prefix":"10.1016","volume":"12","author":[{"given":"Amy","family":"Lockefeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapneel","family":"Anaokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.04.011_b0005","first-page":"10106","article-title":"Mirabegron improves sleep measures, nocturia, and lower urinary tract symptoms in those with urinary symptoms associated with disordered sleep","volume":"27","author":"Petrossian","year":"2020","journal-title":"Can J Urol"},{"key":"10.1016\/j.euf.2026.04.011_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/TCRM.S269318","article-title":"Assessing quality-of-life of patients taking mirabegron for overactive bladder","volume":"19","author":"Shaw","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.euf.2026.04.011_b0015","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jash.2018.08.001","article-title":"Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome","volume":"12","author":"White","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.euf.2026.04.011_b0020","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40264-021-01095-7","article-title":"Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study","volume":"44","author":"Hoffman","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.euf.2026.04.011_b0025","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iju.13218","article-title":"Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: results of a Japanese post-marketing study","volume":"23","author":"Katoh","year":"2016","journal-title":"Int J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:26:14Z","timestamp":1786080374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405456926000611"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.04.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Singh and Srivastav\u2019s Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. 2026;12:393\u2013402","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.03.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}